Wealth Effects LLC Acquires 24,750 Shares of Perspective Therapeutics, Inc. (NYSE:CATX)

Wealth Effects LLC raised its stake in shares of Perspective Therapeutics, Inc. (NYSE:CATX) by 186.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 38,000 shares of the company’s stock after purchasing an additional 24,750 shares during the quarter. Wealth Effects LLC’s holdings in Perspective Therapeutics were worth $121,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently modified their holdings of the company. nVerses Capital LLC acquired a new stake in Perspective Therapeutics in the 3rd quarter valued at $57,000. Trueblood Wealth Management LLC lifted its holdings in shares of Perspective Therapeutics by 37.0% during the fourth quarter. Trueblood Wealth Management LLC now owns 22,236 shares of the company’s stock valued at $71,000 after acquiring an additional 6,000 shares during the period. SG Americas Securities LLC grew its holdings in shares of Perspective Therapeutics by 41.3% in the 4th quarter. SG Americas Securities LLC now owns 26,088 shares of the company’s stock worth $83,000 after purchasing an additional 7,627 shares during the last quarter. US Bancorp DE increased its position in shares of Perspective Therapeutics by 142.7% during the 3rd quarter. US Bancorp DE now owns 6,576 shares of the company’s stock worth $88,000 after purchasing an additional 3,866 shares in the last quarter. Finally, Point72 DIFC Ltd acquired a new stake in shares of Perspective Therapeutics during the 2nd quarter worth about $118,000. 54.66% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts have weighed in on CATX shares. Royal Bank of Canada reaffirmed an “outperform” rating and set a $16.00 price objective on shares of Perspective Therapeutics in a research note on Tuesday, January 14th. Wedbush restated an “outperform” rating and set a $11.00 price target on shares of Perspective Therapeutics in a research report on Friday, January 24th. Oppenheimer dropped their price target on Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating for the company in a report on Friday, November 22nd. UBS Group initiated coverage on Perspective Therapeutics in a research note on Thursday, October 24th. They issued a “buy” rating and a $20.00 price objective on the stock. Finally, Bank of America lowered Perspective Therapeutics from a “buy” rating to a “neutral” rating and lowered their target price for the company from $24.00 to $5.00 in a research note on Monday, November 25th. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Perspective Therapeutics has an average rating of “Moderate Buy” and an average target price of $15.14.

Insider Buying and Selling at Perspective Therapeutics

In other news, Director Heidi Henson purchased 25,975 shares of the business’s stock in a transaction that occurred on Wednesday, December 4th. The shares were acquired at an average cost of $3.85 per share, for a total transaction of $100,003.75. Following the transaction, the director now directly owns 25,975 shares of the company’s stock, valued at approximately $100,003.75. The trade was a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this link. Also, CEO Johan M. Spoor acquired 14,500 shares of the firm’s stock in a transaction that occurred on Monday, November 25th. The shares were purchased at an average price of $3.78 per share, with a total value of $54,810.00. Following the acquisition, the chief executive officer now owns 152,072 shares of the company’s stock, valued at approximately $574,832.16. This trade represents a 10.54 % increase in their position. The disclosure for this purchase can be found here. Over the last ninety days, insiders have acquired 67,570 shares of company stock valued at $256,789. 3.52% of the stock is currently owned by insiders.

Perspective Therapeutics Stock Performance

CATX stock opened at $3.69 on Wednesday. Perspective Therapeutics, Inc. has a twelve month low of $2.70 and a twelve month high of $19.05. The business has a fifty day moving average of $3.62 and a 200-day moving average of $9.68.

Perspective Therapeutics (NYSE:CATX) last released its earnings results on Tuesday, November 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.21). Perspective Therapeutics had a negative net margin of 4,096.66% and a negative return on equity of 27.40%. The company had revenue of $0.37 million for the quarter. On average, research analysts expect that Perspective Therapeutics, Inc. will post -0.88 EPS for the current year.

Perspective Therapeutics Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.